论文部分内容阅读
High frequency stimulation (HFS) of the subthalamic nucleus (STN) is an effica cious symptomatic treatment for Parkinson’s disease. We have analysed the genet ic status of a series of consecutive parkinsonian patients implanted for STN HFS and compared the outcome of five carrying mutations in the parkin gene with tha t of the non-parkin group. All patients obtained sustained control of PD sympto ms and achieved functional improvement; in the parkin group the UPDRS motor scor e improved by 56.4%, the levodopa equivalent daily dosage was reduced by 75.5% . Postoperative medications were reduced more in parkin than in non-parkin pati ents. We confirm that the current inclusion criteria for STN HFS do not exclude patients carrying mutations in the parkin gene; their clinical outcome is compar able to that of the non-parkin group.
High frequency stimulation (HFS) of the subthalamic nucleus (STN) is an effica cious symptomatic treatment for Parkinson’s disease. We have analyzed the gene status of a series of consecutive parkinsonian patients implanted for STN HFS and compared the outcome of five carrying mutations in the parkin gene with tha t of the non-parkin group. All patients acquired sustained control of PD sympto ms and achieved functional improvement; in the parkin group the UPDRS motor scor e improved by 56.4%, the levodopa equivalent daily dosage was reduced by 75.5 %. Postoperative medications were reduced more in parkin than in non-parkin pati ents. We confirm that the current inclusion criteria for STN HFS do not exclude patients carrying mutations in the parkin gene; their clinical outcome is compar able to that of the non- parkin group.